Montelukast Therapeutic Levels and Clinical Benefits

Onset of Therapeutic Effect

Montelukast begins producing clinical benefits within 1 day of starting therapy, with onset of action occurring by the second day of daily treatment, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
The onset of action occurs by the second day of daily treatment for allergic rhinitis symptoms, according to the American Academy of Allergy, Asthma, and Immunology 1, 2

Montelukast demonstrates a long elimination half-life that supports once-daily dosing and maintains therapeutic drug levels throughout the 24-hour dosing interval, as stated by the National Institutes of Health 3
The medication can be taken without regard to meals, though administration with meals may improve gastrointestinal tolerability, as suggested by the American Gastroenterological Association 4
Evening or bedtime administration is recommended based on the drug's pharmacodynamic profile, particularly for asthma management, as advised by the National Heart, Lung, and Blood Institute 4, 5

Montelukast is less effective than intranasal corticosteroids for allergic rhinitis and should not be considered first-line therapy when intranasal steroids are appropriate, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
The FDA black box warning regarding neuropsychiatric events necessitates monitoring for unusual behavioral or mood changes when starting montelukast, despite its rapid therapeutic onset, as warned by the Food and Drug Administration 6, 4, 3
Montelukast provides continuous control rather than acute symptom relief, distinguishing it from rescue medications like short-acting beta-agonists, as stated by the National Institutes of Health 3